Forian Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 24, 2022
Forian Inc. (Nasdaq:FORA) will announce its financial results for Q4 and year-end 2021 on March 24, 2022, post-market close. A conference call and webcast will follow at 4:30 p.m. ET. Highlights for 2021 include strong organic revenue growth from new clients in healthcare, market leadership in Seed-to-Sale and Track and Trace technologies following a merger with Helix Technologies, and several government contract wins. The company emphasizes ongoing investments in innovative products for the healthcare and cannabis sectors.
- Accelerated organic revenue growth with over 20 new healthcare clients in 2021.
- Leading market share in Seed-to-Sale and Track and Trace technologies.
- New state contract wins and renewals for government solutions.
- Continued investment in differentiated product offerings.
- None.
NEWTOWN, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Forian Inc. (Nasdaq:FORA), a provider of software, data, and analytics-enabled services for the healthcare and cannabis industries, will announce its financial results for the fourth quarter and year ending on December 31, 2021 on Thursday, March 24, 2022 after the close of the market. The Company will host a conference call and webcast at 4:30 p.m. (ET) on March 24, 2022 to discuss the results.
To access the conference call, from the US dial (855) 940-5323 or for international calls dial (929) 517-0423, and enter Conference ID 1275289. The webcast will be available live at https://edge.media-server.com/mmc/p/7q8gypu2. This information is also available on our website at www.forian.com/investors. The earnings release along with a replay of the call promptly following its conclusion will be available at the same site.
Forian 2021 highlights to be discussed on the call include:
- Accelerated organic revenue growth from the launch of the Company’s information products within the healthcare market with over 20 new clients contracted in 2021 and growing sales momentum coming into 2022;
- Leading market share positions in the Seed-to-Sale and Track and Trace technologies from the business combination with Helix Technologies completed on March 2, 2021;
- Several new state contract wins and renewals for the Company’s government solutions; and
- Continued long-term investments in differentiated new product offerings for the healthcare and cannabis markets.
About Forian
Forian provides a unique suite of SaaS solutions, data management capabilities and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries, manufacturers, cultivators, and regulators. For more information, please visit the Company’s website at www.forian.com.
Cautionary Statements Regarding Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond the control of Forian, and are not guarantees of future results, such as statements about the anticipated benefits of the business combination transaction involving Forian, Medical Outcomes Research Analytics, LLC and Helix Technologies, Inc., future financial and operating results, company strategy and intended product offerings and market positioning. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Forian’s business, operations, strategy and goals; Forian’s ability to execute on its strategy; the timing of the introduction of new product offerings; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Forian’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 31, 2021, and elsewhere in Forian’s filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof, and Forian undertakes no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
Media and Investor Contact:
267-225-6263
forian.com/investors
ir@forian.com
FAQ
When will Forian Inc. announce its Q4 financial results?
What time is the Forian Inc. conference call scheduled?
What significant achievements will Forian discuss during the call?
Where can I access the Forian Inc. conference call webcast?
